Viking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety
Viking Therapeutics Inc (NASDAQ:VKTX) announced that new clinical data from the company’s VK2735 obesity program were highlighted in two poster presentations at ObesityWeek 2024. Viking is evaluating both subcutaneous and oral formulations of VK2735 in clinical trials.
Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...
Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $72.88. Lee covers ...
13d
Viking Therapeutics Inc (VKTX) showcases promising clinical advancements and robust cash reserves, despite increased expenses ...
Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for ...
Obesity pill data released by Viking Therapeutics Inc and AstraZeneca Plc at a big conference foreshadowed an increasingly ...
On Friday, Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $78.03 which represents a slight increase of $4.81 or 6.57% from the prior close of $73.22. The stock opened at ...
Q3 2024 Earnings Call Transcript October 23, 2024 Viking Therapeutics, Inc. beats earnings expectations. Reported EPS is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback